Clinical Trials Logo

Stage I Renal Cell Cancer clinical trials

View clinical trials related to Stage I Renal Cell Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02885649 Terminated - Clinical trials for Clear Cell Renal Cell Carcinoma

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Start date: December 5, 2017
Phase: Early Phase 1
Study type: Interventional

This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.

NCT ID: NCT02767921 Terminated - Clinical trials for Stage III Prostate Cancer

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Start date: August 2, 2016
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer. Recombinant EphB4-HSA fusion protein may block an enzyme needed for tumor cells to multiply and may also prevent the growth of new blood vessels that bring nutrients to the tumor. Giving recombinant EphB4-HSA fusion protein before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

NCT ID: NCT02170389 Terminated - Clinical trials for Recurrent Renal Cell Carcinoma

Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer

Start date: October 14, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies vaccine therapy before surgery in treating patients with kidney cancer that has not spread to nearby lymph nodes or to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells when they are infused back into the body.